Caxton Associates (New York)’s Bristol-Myers Squibb BMY Stock Holding History

Caxton Associates (New York)’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,369	Closed	-$1.48M	–	483
2024 Q1	$1.48M	Buy	27,369 +1,430	+6%	+$72.8K	0.08%	168
2023 Q4	$1.33M	Hold	25,939	–	–	0.07%	186
2023 Q3	$1.51M	Buy	25,939 +14,204	+121%	+$870K	0.21%	85
2023 Q2	$750K	Buy	11,735 +1,771	+18%	+$119K	0.11%	191
2023 Q1	$691K	Sell	9,964 -15,940	-62%	-$1.12M	0.1%	208
2022 Q4	$1.86M	Buy	+25,904	New	+$1.95M	0.12%	48
2022 Q3	–	Sell	-8,082	Closed	-$622K	–	491
2022 Q2	$622K	Buy	+8,082	New	+$616K	0.06%	220
2020 Q3	–	Sell	-11,019	Closed	-$648K	–	329
2020 Q2	$648K	Buy	+11,019	New	+$659K	0.06%	99
2018 Q2	–	Sell	-4,572	Closed	-$289K	–	381
2018 Q1	$289K	Buy	+4,572	New	+$294K	0.01%	291
2017 Q3	–	Sell	-6,600	Closed	-$368K	–	496
2017 Q2	$368K	Buy	+6,600	New	+$359K	0.01%	419

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caxton Associates (New York)'s BMY Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 27,369 shares — an estimated $1.48M sold.

Caxton Associates (New York) first reported a position in BMY in Q2 2017 and held it in 10 quarters. The position peaked at $1.86M in Q4 2022. 2,154 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Caxton Associates (New York) reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Caxton Associates (New York) sold 27,369 Bristol-Myers Squibb shares in Q2 2024, an estimated $1.48M.
Caxton Associates (New York) first reported a position in Bristol-Myers Squibb in Q2 2017 and held it in 10 quarters.
Caxton Associates (New York)'s Bristol-Myers Squibb position peaked at $1.86M in Q4 2022.
2,154 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.